Clinical Trial Finder

Inclusion Criteria:

• - Participants must have a weight of ≥ 20 kg.

• - Participant must have an age and sex specific BMI value no lower in range than the fifth percentile on the growth chart for children and adolescents.

• - Participant is able to swallow the study medication tablet.

• - Diagnosis of chronic plaque psoriasis for at least 6 months prior to screening.

• - Has mild to moderate plaque psoriasis at screening and Study Visit 1 as defined by: - Psoriasis Area Severity Index score 2-15, - Body surface area 2-15%, and.

• - Static Physician Global Assessment score of 2-3 (mild to moderate) - Disease inadequately controlled by or inappropriate for topical therapy for psoriasis.

Exclusion Criteria:

• - Guttate, erythrodermic, or pustular psoriasis at screening and Study Day 1.

• - Psoriasis flare or rebound within 4 weeks prior to screening.

• - Active tuberculosis (TB) or a history of incompletely treated TB per local guidelines.

• - History of recurrent significant infections.

• - Active infection or infection treated with antibiotic treatment within 14 days of Study Day 1.

• - Any history of or active malignancy or myeloproliferative or lymphoproliferative disease.

• - Current use of the following therapies that may have a possible effect on psoriasis: - Conventional systemic therapy for psoriasis within 28 days prior to Study Day 1 (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters).

• - Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 28 days prior to Study Day 1.

• - Biologic therapy: - Etanercept (or biosimilar) treatment 28 days prior to Study Day 1.

• - Adalimumab (or biosimilar) treatment 10 weeks prior to Study Day 1.

• - Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to Study Day 1.

• - Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) within 24 weeks prior to Study Day 1.

• - Use of tanning booths or other ultraviolet light sources.

• - Answer "Yes" to any question on the Columbia-Suicide Severity Rating Scale during screening or at Study Day 1.

• - Female participant of childbearing potential with a positive pregnancy test assessed at screening and/or Study Day 1 by a serum and/or urine pregnancy test.

Arms

Interventions